CASI Pharmaceuticals (CASIF)

OTHER OTC:CASIF

CASIF

CASI Pharmaceuticals

RESEARCH TOOLSreports

CASI Pharmaceuticals (CASIF) Price & Analysis

478 Followers

CASIF Stock Chart & Stats

$1.06

-$0.35(-10.90%)

At close: Jan 08 4:00 PM EST

$1.06

-$0.35(-10.90%)

Day’s Range― - ―

52-Week Range$0.05 - $3.09

Previous CloseN/A

VolumeN/A

Average Volume (3M)219.83K

Market Cap

$2.24M

Enterprise Value$16.66M

Total Cash (Recent Filing)$4.68M

Total Debt (Recent Filing)$18.86M

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Apr 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.68

Shares Outstanding15,492,681

10 Day Avg. Volume60,876

30 Day Avg. Volume219,829

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)23.45

Price to Sales (P/S)1.52

P/FCF Ratio-1.47

Enterprise Value/Market Cap7.45

Enterprise Value/Revenue0.62

Enterprise Value/Gross Profit1.73

Enterprise Value/Ebitda-0.40

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-1.41

Revenue Forecast (FY)$70.35M

Bulls Say, Bears Say

Bulls Say

Debt ReductionThe sale of the China business to Kaixin allows the company to eliminate $20M of existing debt, improving its financial position.

Product DevelopmentCID-103 has shown superior activity and reduced toxicity compared to existing CD38 inhibitors in preclinical and Phase 1 studies, indicating strong potential for successful development.

Strategic ManagementThe appointment of David Cory as the company’s new CEO, who has more than 30 years of experience in the biotech and pharma sectors, is seen as beneficial for the company’s new direction.

Bears Say

Financial PerformanceCASI reported revenues of $4.2M and a net loss of $0.86 per share for the quarter, which was below the consensus estimated revenue of $6.3M and net loss of $0.47 per share.

Licensing And RevenueThe company received a Termination Process Letter to withdraw the Evomela license following a wind-down period, which impacts the company's Chinese business revenues.

Revenue ImpactThe company reported lower-than-expected revenues, which fell 16% year-over-year, primarily due to increased generic competition for Evomela in China.

CASI Pharmaceuticals News

CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role

The latest update is out from CASI Pharmaceuticals ( ($CASIF) ). CASI Pharmaceuticals announced a leadership change, reporting...

1M ago

CASIF FAQ

What was CASI Pharmaceuticals’s price range in the past 12 months?

CASI Pharmaceuticals lowest stock price was $0.05 and its highest was $3.09 in the past 12 months.

What is CASI Pharmaceuticals’s market cap?

CASI Pharmaceuticals’s market cap is $2.24M.

When is CASI Pharmaceuticals’s upcoming earnings report date?

CASI Pharmaceuticals’s upcoming earnings report date is Apr 29, 2026 which is in 18 days.

How were CASI Pharmaceuticals’s earnings last quarter?

CASI Pharmaceuticals released its earnings results on Nov 14, 2025. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.28.

Is CASI Pharmaceuticals overvalued?

According to Wall Street analysts CASI Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CASI Pharmaceuticals pay dividends?

CASI Pharmaceuticals does not currently pay dividends.

What is CASI Pharmaceuticals’s EPS estimate?

CASI Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CASI Pharmaceuticals have?

CASI Pharmaceuticals has 15,492,681 shares outstanding.

What happened to CASI Pharmaceuticals’s price movement after its last earnings report?

CASI Pharmaceuticals reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -5.556%.

Which hedge fund is a major shareholder of CASI Pharmaceuticals?

Currently, no hedge funds are holding shares in CASIF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CASI Pharmaceuticals

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc?RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.